Orofacial complications from immune checkpoint inhibitors: A retrospective analysis from two academic medical centers.
Head Neck
; 46(8): 1865-1872, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38258988
ABSTRACT
BACKGROUND:
Immune checkpoint inhibitors (ICIs) are FDA-approved for various cancers, yet their orofacial immune-related adverse events (irAEs) remain poorly understood. Our two-center retrospective study aims to better understand the prevalence and nature of these orofacial irAEs.METHODS:
We retrospectively collected demographics, ICI details, and onset of orofacial irAEs in ICI-treated patients at University of California San Francisco and City of Hope (2013-2021). Orofacial irAEs were identified by ICD-10 codes and data categorized as dry mouth/xerostomia, oral mucosal lesions, and orofacial neuropathies. Patients with pre-existing orofacial conditions resembling the reported irAEs were excluded.RESULTS:
Among 3768 ICI-treated patients, 408 (10.8%) developed 467 orofacial irAEs oral mucosal diseases (41.4%), dry mouth/xerostomia (41.0%), and orofacial neuropathies (17.6%). Notably, head and neck cancers had the highest incidence of orofacial irAEs.CONCLUSIONS:
Orofacial irAEs are relatively common in patients receiving ICIs, necessitating careful monitoring and management of these complications during and after the treatment.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Centros Médicos Académicos
/
Inhibidores de Puntos de Control Inmunológico
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Head Neck
Asunto de la revista:
NEOPLASIAS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos